Dallas, Texas 02/25/2014 (FINANCIALSTRENDS) – HemispherxBioPharma, Inc (NYSEMKT:HEB) which offers a suite of pharmaceutical company which offers a variety of specialty products which manufacture clinical development drugs. The company is also engaged in the development of drugs which offer therapy for a range of debilitating disorders.
HemispherxBioPharma, Inc(NYSEMKT:HEB) main product line is the Alferon N Injection, along with this product, the other experimental products include Ampligen as well as Alferon LDO. Experimental RNA nucleic acid based drug, Ampligen is also known globally for handling immune systems problems such as the Chronic Fatigue Syndrome.
HemispherxBioPharma, Inc(NYSEMKT:HEB) offers a technology platform which brings components which bring potential treatment which are life threatening. However, for HEB the problem is that two of its products are experimental in nature. These are regarded as effective yet do not have the mandate of the regulatory authorities. This has meant that these two drugs are available only as part of the clinical trials.
HemispherxBioPharma, Inc(NYSEMKT:HEB) however now also holds patents and a product it can market – Alferon N Injection- which is approved in the US as well as Argentina. In the latter country the injection will be available as Naturaferon. The use of this injection is permitted when the patient is found to fail to respond to recombinant interferon. Patients who suffer from Chronic Active Hepatitis C too are allowed to use this drug form. HemispherxBioPharma, Inc (NYSEMKT:HEB) owns and operates GMP certified facility in the US, besides other commercial products. The company has since recorded that the research of so many years on primate testing has led to the increase in the number of broad spectrum as well as pandemic influenza vaccine. These are carried out across international borders. And this has led to the development of FluMist. This is recognized as the one product which is expected to work as a vaccine to protect seasonal influenza.